[Long-term study on a new beta2-sympathicomimetic agent and a combination of an oral theophylline-ethylenediamine with retard effect and hexoprenaline (author's transl)].

The effects of a treatment with a new beta2-adrenergic agent (hexoprenaline, Etoscol) as well as a combined therapy of theophylline (Euphylin retard) with the Etoscol on the total resistance were studied on two groups of patients. The therapy resulted in a significant decrease of the total resistance and the combined therapy showed an additional decrease of the resistance values.